A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Empliciti
(United States) [Available]Synonyms :
Elotuzumab
Class :
 Antineoplastics and Monoclonal Antibody
Brand Name :
Empliciti
(United States) [Available]Synonyms :
Elotuzumab
Class :
 Antineoplastics and Monoclonal Antibody
Dosage Forms & Strengths  Â
Injection, lyophilized powder for reconstitution  Â
300mg per vial  Â
400mg per vial  Â
Lenalidomide + dexamethasone
Indicated for multiple myeloma with 1 or 3 previous treatments
one therapeutic cycle = 28 days
Therapy should be continued until the illness gets worse or the toxicity gets too much to handle
Note: As stated in Administration, premedicate before to each dosage
Cycles 1-2 = Days 1–8 and 15–22: elotuzumab 10-mg/kg IV
Days 1–21 = Lenalidomide 25 mg orally
Days 1-22= Dexamethasone 28 mg orally in 24 hrs before elotuzumab
Cycle 3 and further
Day 1–Day 15 = Lenalidomide 25 mg orally
Days 1–21: elotuzumab (10 mg/kg) IV
Days 1-15 elotuzumab with 28 mg orally dexamethasone 24 hrs before elotuzumab
Days 8, 22 without elotuzumab: 40 mg of dexamethasone
Pomalidomide + dexamethasone
Suitable for multiple myeloma + 2 regimens
One therapy cycle = every 28 days
Cycles 1-2
Days 1-8 and 15–22 = elotuzumab 10 mg/kg IV
Days 1–21= On Days 1, 8, 15, and 22, when elotuzumab with pomalidomide 4 mg orally
Dexamethasone 28 mg orally given 3–24 hours before elotuzumab
Cycle 3 and subsequent
IV elotuzumab (20 mg/kg) on Day 1; Days 1–21: 4 mg of pomalidomide PO
Day 1 with elotuzumab, dexamethasone 8 mg
Orally administer 3–24 hours before to elotuzumab
Days 8, 15, and 22 without elotuzumab: Dexamethasone 40 mg (Age= 75 years) or 20 mg (Age= 75 years above)
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of severe and potentially fatal infection   
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections   
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections   
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections   
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections   
influenza virus vaccine h n live
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
influenza virus vaccine live trivalent
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections   
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
poliovirus vaccine live trivalent
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be a reduced response to the vaccine   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk of developing rare infections   
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be a reduced response to the skin test   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be a reduced response to the skin test   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk of nerve damage   
when both drugs are combined, there may be an increased risk of nerve damage
it may enhance the adverse effects when combined with aducanumab
Action and spectrum:Â
This drugs activates humanized IgG1 antibodies to target specifically a protien SLAMF7. It increases the anti-myeloma activity in vitro by directly activating natural killer cells through the Fc receptor and SLAMF7 pathway. Elotuzumab targets SLAMF7 on myeloma cells and interacts with Fc receptors on immune cells to aid in myeloma cell death by NK cell-mediated antibody-dependent cellular cytotoxicity and macrophage-mediated antibody-dependant cellular phagocytosis (ADCC).Â
Frequency definedÂ
1-10%Â
Chest painÂ
HypersensitivityÂ
HypoesthesiaÂ
Night sweatsÂ
Second primary malignanciesÂ
>10%Â
CataractsÂ
DiarrheaÂ
ConstipationÂ
Oropharyngeal painÂ
nasopharyngitisÂ
upper respiratory tract infectionÂ
pneumoniaÂ
Â
0.1-1%Â
Anaphylactic reactionÂ
Frequency not definedÂ
HyperglycemiaÂ
hypocalcemiaÂ
low bicarbonateÂ
hyperkalemiaÂ
LeukopeniaÂ
ThrombocytopeniaÂ
Deep vein thrombosisÂ
Black Box Warning:Â
During and soon after your treatment with these medications, you will need to use birth control to avoid getting pregnant.Â
Contraindication/Caution:Â
Hypersensitivity is associated with this drug and contraindicated.Â
Multiple myeloma, subsequent primary malignancies, and reactions associated with infusion.Â
Pregnancy Warnings:Â
Pregnancy category:Â
AU TGA pregnancy category: DÂ
US FDA pregnancy category: Not assignedÂ
Lactation:Â
Excretion of the drug into human breast milk is unknownÂ
Pregnancy Categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology:Â
Pharmacodynamics:Â
Elotuzumab involves monoclonal antibody humanized IgG1 selectively targets SLAMF7 on myeloma cells and helps in the destruction of myeloma cells through antibody-dependent cellular cytotoxicity (ADCC).Â
Pharmacokinetics:Â
AbsorptionÂ
The bioavailability is higher.Â
DistributionÂ
The volume of distribution showed 5.7 liters.Â
MetabolismÂ
It metabolizes peptides and amino acids.Â
Administration:Â
The route of administration is intravenously.Â
Generic Name: elotuzumabÂ
Pronunciation: EH-loh-TOO-zoo-mabÂ
Why do we use Elotuzumab?Â
Elotuzumab is an anti-cancer medication that boosts immune function by targeting the SLAMF7 protein. When multiple myeloma has not responded to prior treatments, it is used in conjunction with other cancer therapies.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
